Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 662

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Open access
Ritchlin, Christopher, Rahman, Proton, Kavanaugh, Arthur, McInnes, Iain B, Puig, Lluis, Li, Shu, Wang, Yuhua, Shen, Yaung-Kaung, Doyle, Mittie K, Mendelsohn, Alan M, Gottlieb, Alice B, Perate, Michelle, Whitman, Mary, Dooley, Lisa T, Alten, R, Birbara, C, Boh, E, Braun, J, Budd, J, Chattapadhyay, C, Chudzik, D, Claudepierre, P, Cooper, R, Drescher, E, Dutz, J, Edwards, C, Elewski, B, El-Kadi, H, Erlacher, L, Flipo, R, Fretzin, SA, George, E, Gladstein, G, Griffin, RM, Grisanti, MW, Guenther, L, Gulliver, W, Hobbs, K, Huang, E, Ilivanova, E, Jeka, S, Khraishi, M, Kokhan, M, Korman, N, Kunynetz, R, Leonardi, CL, Lessard, C, Lindquist, U, Martin, A, Matheson, RT, Murphy, FT, Nasonov, E, Palmer, W, Papp, K, Rech, J, Rell-Bakalarska, M, Rich, P, Rosen, C, Rudin, A, Ruppert-Roth, A, Scheinecker, C, Seigel, S, Shaikh, S, Sheeran, T, Shergy, WJ, Siegel, EL, Sierakowski, S, Sofen, H, Szanto, S, Tahir, H, Telegdy, E, Toth, D, Walker, D, Wilson, AG, Witt, M, Wollenhaupt, J, Zoschke, D, Zubrzycka, A·2014·Annals of the Rheumatic Diseases

Abstract

OBJECTIVE: Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological anti-tumour necrosis factor (TNF) agents. METHODS: In this phase 3, multicentre, placebo-controlled trial, 312 adults with active PsA were randomised (stratified by site, weight (≤100 kg/>100 kg), methotrexate use) to ustekinumab 45 mg or 90 mg at week 0, week 4, q12 weeks or placebo at week 0, week 4, week 16 and crossover to ustekinumab 45 mg at week 24, week 28 and week 40. At week 16, patients with <5% improvement in tender/swollen joint counts entered blinded early escape (placebo→45 mg, 45 mg→90 mg, 90 mg→90 mg). The primary endpoint was ≥20% improvement in American College of Rheumatology (ACR20) criteria at week 24. Secondary endpoints included week 24 Health Assessment Questionnaire-Disability Index (HAQ-DI) improvement, ACR50, ACR70 and ≥75% improvement in Psoriasis Area and Severity Index (PASI75). Efficacy was assessed in all patients, anti-TNF-naïve (n=132) patients and anti-TNF-experienced (n=180) patients. RESULTS: More ustekinumab-treated (43.8% combined) than placebo-treated (20.2%) patients achieved ACR20 at week 24 (p<0.001). Significant treatment differences were observed for week 24 HAQ-DI improvement (p<0.001), ACR50 (p≤0.05) and PASI75 (p<0.001); all benefits were sustained through week 52. Among patients previously treated with ≥1 TNF inhibitor, sustained ustekinumab efficacy was also observed (week 24 combined vs placebo: ACR20 35.6% vs 14.5%, PASI75 47.1% vs 2.0%, median HAQ-DI change -0.13 vs 0.0; week 52 ustekinumab-treated: ACR20 38.9%, PASI75 43.4%, median HAQ-DI change -0.13). No unexpected adverse events were observed through week 60. CONCLUSIONS: The interleukin-12/23 inhibitor ustekinumab (45/90 mg q12 weeks) yielded significant and sustained improvements in PsA signs/symptoms in a diverse population of patients with active PsA, including anti-TNF-experienced PsA patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2013-204655

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 662

Metadata

Authors
Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I. B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., Gottlieb, A. B., Perate, M., Whitman, M., Dooley, L. T., Alten, R., Birbara, C., Boh, E., Braun, J., Budd, J., Chattapadhyay, C., Chudzik, D., Claudepierre, P., Cooper, R., Drescher, E., Dutz, J., Edwards, C., Elewski, B., El-Kadi, H., Erlacher, L., Flipo, R., Fretzin, S., George, E., Gladstein, G., Griffin, R., Grisanti, M., Guenther, L., Gulliver, W., Hobbs, K., Huang, E., Ilivanova, E., Jeka, S., Khraishi, M., Kokhan, M., Korman, N., Kunynetz, R., Leonardi, C., Lessard, C., Lindquist, U., Martin, A., Matheson, R., Murphy, F., Nasonov, E., Palmer, W., Papp, K., Rech, J., Rell-Bakalarska, M., Rich, P., Rosen, C., Rudin, A., Ruppert-Roth, A., Scheinecker, C., Seigel, S., Shaikh, S., Sheeran, T., Shergy, W., Siegel, E., Sierakowski, S., Sofen, H., Szanto, S., Tahir, H., Telegdy, E., Toth, D., Walker, D., Wilson, A., Witt, M., Wollenhaupt, J., Zoschke, D., & Zubrzycka, A.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2014-06
Volume
73
Issue
6
Pages
990-999
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2137101132
Cited by
662
References
31
FWCI
55.09
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. https://app.cochat.ai/papers/10.1136/annrheumdis-2013-204655
The paper
Ritchlin, C., Rahman, P., Kavanaugh, A., McInnes, I. B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., Gottlieb, A. B., Perate, M., Whitman, M., Dooley, L. T., Alten, R., Birbara, C., Boh, E., Braun, J., Budd, J., . . . Zubrzycka, A. (2014). Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2013-204655

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.